Overview

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Patients With Primary Biliary Cholangitis

Status:
Terminated
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in patients with primary biliary cholangitis (PBC).
Phase:
Phase 2
Details
Lead Sponsor:
Arena Pharmaceuticals